Vascular Endothelial Growth Factor Inhibitor [EPC]

185199 reported adverse events

Drugs of this class: AFLIBERCEPT RANIBIZUMAB RANIBIZUMAB-EQRN RANIBIZUMAB-NUNA AFLIBERCEPT-AYYH AFLIBERCEPT-JBVF BEVACIZUMAB BEVACIZUMAB-ADCD BEVACIZUMAB-AWWB BEVACIZUMAB-BVZR BEVACIZUMAB-MALY

These side effects are most commonly reported by patients taking drugs of the Vascular Endothelial Growth Factor Inhibitor [EPC] class:

# Side effect Count
0 DEATH 25058
1 OFF LABEL USE 17722
2 DIARRHOEA 8238
3 DISEASE PROGRESSION 8232
4 FATIGUE 7291
5 NAUSEA 7196
6 HYPERTENSION 6950
7 VOMITING 5470
8 DRUG INEFFECTIVE 5363
9 ANAEMIA 4779
See all common reactions for Vascular Endothelial Growth Factor Inhibitor [EPC]

Drugs of the Vascular Endothelial Growth Factor Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 RETINAL PIGMENT EPITHELIAL TEAR 505 0.7277
1 NON-INFECTIOUS ENDOPHTHALMITIS 565 0.6655
2 DIABETIC RETINAL OEDEMA 312 0.6142
3 DETACHMENT OF RETINAL PIGMENT EPITHELIUM 517 0.5809
4 SUBRETINAL FLUID 614 0.5618
5 ENDOPHTHALMITIS 3242 0.5399
6 CHOROIDAL NEOVASCULARISATION 448 0.5221
7 VITRECTOMY 305 0.5117
8 SUSPECTED TRANSMISSION OF AN INFECTIOUS AGENT VIA PRODUCT 551 0.4426
9 AGE-RELATED MACULAR DEGENERATION 592 0.3897
See all enriched reactions for Vascular Endothelial Growth Factor Inhibitor [EPC]